SPOTLIGHT: Introgen touts cancer data

Introgen Therapeutics is reporting that about half of the patients in a Phase II trial of INGN 225 for non small cell lung cancer responded to the therapy in combination with chemotherapy. Researchers reported a 52 percent tumor response rate to INGN 225--which contains the p53 gene--and that 41 percent of the volunteers were alive one year after starting treatment. Historically, tumor responses to second-line chemotherapy are between 6 and 30 percent and most patients survive for less than 6 months. Release